BioSpace News Archive

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

Xenon Pharmaceuticals Inc. announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL.

May 28, 2024
·
7 min read
Biotech Bay

Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

Sight Sciences, Inc. announced the results as published in the journal Clinical Ophthalmology of a new analysis of the ROMEO study data.

May 28, 2024
·
7 min read
Pharm Country

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

Lisata Therapeutics, Inc. today announced that management will participate in the following events in June.

May 28, 2024
·
2 min read
Business

CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider

CorMedix Inc. today announced that it has entered into a multi-year commercial supply contract with a top tier midsized dialysis provider for the supply of DefenCath ® (taurolidine and heparin).

May 28, 2024
·
3 min read
Pharm Country

NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the ASCP Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar

NRx Pharmaceuticals, Inc. announced presentation of its Phase 2b/3 trial of NRX-101, entitled “A Randomized, Double-Blind Controlled Comparison of NRX-101 to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior” at the American Society of Clinical Psychopharmacology in Miami Beach, FL.

May 28, 2024
·
7 min read
Drug Development

Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including new Phase 3 clinical study data from its CAHtalyst™ registrational studies of crinecerfont.

May 28, 2024
·
10 min read
Business

IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024

IceCure Medical Ltd. today reported financial results as of and for the three months ended March 31, 2024.

May 28, 2024
·
17 min read
Pharm Country

PreciseDx Announces Poster Presentation at The 2024 American Society of Clinical Oncology Annual Meeting

PreciseDx today announced its attendance and participation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

May 28, 2024
·
4 min read
Pharm Country

PTC Therapeutics Announces Validation of Sepiapterin European MAA

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sepiapterin MAA for PKU has been validated and accepted for review by the EMA.

May 28, 2024
·
6 min read
Drug Development

Denovo Biopharma LLC to Present Positive Phase 2b ENLIGHTEN Trial Data for DGM4 Biomarker-Guided DB104 (liafensine) Treatment for Treatment ‑Resistant Depression at the ASCP 2024 Annual Meeting

Denovo Biopharma LLC today announced that positive results for its biomarker-‑guided Phase 2b clinical trial (ENLIGHTEN) designed to assess the efficacy and safety of DB104 (liafensine) in patients with treatment-resistant depression (TRD) will be presented at two sessions at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, FL.

May 28, 2024
·
4 min read